Reaction

Engraftment Syndrome reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 580 reports · 41 co-occurring drugs

As of the last recalculation, Engraftment Syndrome appears in 580 FAERS reports alongside 41 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 509.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Thiotepa	110	509.9	515.8
Fludarabine Phosphate	205	288.8	290.3
Melphalan Hydrochloride	139	261.3	262.8
Melphalan	122	243.5	244.8
Busulfan	90	242.8	244.2
Anti-Thymocyte Globulin (Rabbit)	22	101.7	102.0
Cyclophosphamide Injection, Solution	231	77.2	77.3
Cyclophosphamide	231	77.2	77.3
Cyclophosphamide For Injection	231	77.2	77.3
Micafungin Sodium	16	69.6	69.7
Mesna Injection	14	62.3	62.4
Mesna	14	61.1	61.2
Etoposide	88	50.5	50.5
Dalteparin Sodium	14	48.6	48.7
Tacrolimus	156	48.5	48.6
Tacrolimus Ointment 0.1%	130	48.0	48.0
Tacrolimus Extended-Release Capsules	130	47.9	47.9
Filgrastim	46	47.6	47.6
Cytarabine	61	40.6	40.6
Ganciclovir	11	39.3	39.3
Amphotericin B	13	38.1	38.1
Ganciclovir Sodium	11	38.0	38.0
Cefepime Hydrochloride	16	36.6	36.7
Cyclosporine	94	36.0	36.0
Fluconazole	62	35.4	35.5
Hydrocortisone Sodium Succinate	9	34.9	34.9
Granisetron Hydrochloride	9	31.4	31.4
Mycophenolate Mofetil Hydrochloride	98	30.9	30.9
Cefepime	12	30.7	30.7
Mycophenolate Mofetil	97	30.6	30.6
Ursodiol	17	28.8	28.8
Blinatumomab	8	27.9	27.9
Granisetron	8	27.7	27.8
Acyclovir	76	27.3	27.3
Posaconazole	11	24.7	24.8
Posaconazole Delayed-Release	7	23.1	23.2
Bortezomib	45	19.5	19.5
Voriconazole	16	19.4	19.4
Ifosfamide	10	17.0	17.0
Azacitidine For	8	16.0	16.0
Brentuximab Vedotin	4	14.1	14.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.